Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 2006 May;17 Suppl 4:iv12-4.

Mantle cell lymphoma: an update on management.

Author information

1
Division of Hematologic Oncology, Memorial-Sloan Kettering Cancer Center, New York, NY 10021, USA. A-Zelenetz@ski.mskcc.org

Abstract

Although response rates are increased, the addition of rituximab to induction chemotherapy has not yet been proven to extend the progression-free and overall survival benefits of chemotherapy alone. In first remission, high-dose therapy plus stem cell rescue improves time to treatment failure and progression-free survival when compared with maintenance interferon alpha. However, relapse rate does not reach a plateau. Radioimmunotherapy has substantial single-agent activity and when combined with chemotherapy may provide a platform onto which rituximab or autologous stem cell transplantation can be added. Targeted therapies are also showing promise and may have a role in maintenance and/or initial therapy.

PMID:
16702178
DOI:
10.1093/annonc/mdj992
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center